

Potential of redox therapies in neurodegenerative disorders

Elzbieta Miller^{1,2}, Łukasz Markiewicz³, Jacek Kabziński³, Dominik Odrobina^{4,5}, Ireneusz Majsterek³

¹Department of Physical Medicine, Medical University of Lodz, Hallera Square, 1, Lodz, Poland,

²Neurorehabilitation Ward, III General Hospital in Lodz, Milionowa 14, Lodz, Poland, ³Department of Chemistry and Clinical Biochemistry, Medical University of Lodz, Hallera Square 1, Lodz, Poland,

⁴Department of Pathology, Faculty of Health Sciences, Jan Kochanowski Memorial University of Kielce, Kielce, Poland, ⁵Ophthalmology Clinic Boni Frates Lodziensis, Lodz, Poland

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. CNS structures involved in oxidative/nitrosative stress.
4. Oxidative/nitrosative stress
5. Nrf2-ARE Pathway
6. Nitric oxide and peroxynitrite
7. Carbonyl stress
8. Redox therapies in neurodegeneration
 - 8.1. Ginko Biloba
 - 8.2. Coenzyme Q10
 - 8.3. Selenium
 - 8.4. Curcumin
 - 8.5. Omega-3 fatty acid
 - 8.6. Melatonin
 - 8.7. Cannabinoid
 - 8.8. Vitamin E and C
9. Other redox therapies
 - 9.1. Physical Exercise
10. Neurodegenerative disorders and redox therapies
 - 10.1. Parkinson disease
 - 10.2. Alzheimer Disease
 - 10.3. Glaucoma
 - 10.4. Amyotrophic lateral sclerosis
 - 10.5. Multiple sclerosis
11. Conclusions
12. References

1. ABSTRACT

Recently significant advances have been made to understand the pathophysiological mechanisms of neurodegenerative disorders to provide real therapeutic benefits. There is evidence that persistent inflammation and oxidative stress are the crucial factors of ongoing cell damage in neurodegenerative complex etiology. The variety of reactive oxygen and nitrogen species are the cause of both axonal and neuronal destruction, which is pathological hallmark of neurodegeneration. Therefore, the reduction of oxidative stress is currently one of the main neuroprotective strategies. The World

Health Organization (WHO) estimates that, by 2040, neurodegenerative diseases will be the main cause of death in industrialized countries ahead of the cancers. The redox therapeutic approach can target: degenerative component, inflammatory/autoimmune component and neurodegenerative component. Redox therapy should not be applied uniformly, and must be developed to target specific mechanisms. This review focuses on the main antioxidant therapies that are used in many countries as supplements or even as a standard treatment. Additionally, clinical symptoms of most

common neurodegenerative disorders and central nervous system structures involved in oxidative/nitrosative stress are showed.

2. INTRODUCTION

Neurodegeneration is the hallmark of aging processes characterized by progressive dysfunction of nervous system with specific clinical, morphological and biochemical features. They include Alzheimer's Disease (AD) and other dementias, Parkinson's Disease (PD), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) and less common such as, Huntington's Disease, Prion Diseases, and others. The main clinical symptoms of neurodegeneration are cognitive, motor, and/or behavioral impairment connected with atrophy of central and/or peripheral structures of the nervous system. The World Health Organization (WHO) estimates that, by 2040, neurodegenerative diseases will be the main cause of death in industrialized countries ahead of the cancers (1).

Therefore, the neuroprotective compounds and therapies in prevention and treatment are very needed. Accumulating data showed that there are many similarities mainly on molecular level in different neurodegenerative diseases. Discovering these links might be the main point for new therapeutic strategies. This parallels concern not only oxidative stress but also other typical features of neurodegeneration such as persistent inflammation, atypical protein assemblies and apoptosis. Although no effective treatments are yet available, current studies are focused not only on symptomatic treatment but also on prevention mainly by cytoprotective mechanisms described in this review. The growing body of evidence indicates a leading role of oxidative stress as a cause of neurodegeneration on a molecular level. Oxidative damage may affect not only DNA but also the major proteins of key cellular processes. The redox therapeutic approach can target: degenerative component, inflammatory/autoimmune component and neurodegenerative component. Redox therapy should not be applied uniformly, and must be developed to target specific mechanisms.

The progression of age-dependent neurodegeneration is associated with decreased antioxidants and increased oxidative damage to proteins, DNA and lipids. Oxidative protein modification occurs at a low and persistent level in diverse cells and tissues, and accumulates with aging. This review shows evidence of oxidative/nitrosative injury in main neurodegenerative diseases, discuss effects and challenges of redox therapies both in animal and clinical trials. To achieve this goal, a better understanding of cellular targets and processes involved in neurodegeneration and regeneration is needed. Thus, in this review, we discuss the various redox therapies used in the management of

neurodegenerative diseases, namely AD, PD, MS, Glaucoma, ALS and HD (2).

3. CNS STRUCTURES INVOLVED IN OXIDATIVE/NITROSATIVE STRESS

Normal CNS ageing is characterized by variety of biochemical changes, such as increased oxidative stress, persistent microinflammation and altered energy metabolism (reviewed in Prolla and Mattson 2001 (3)). Furthermore, ageing tends to cause metabolic changes by mechanisms shared with neurodegenerative disorders, such as excitotoxic damage and increased calcium ion influx, leading to cell death by necrosis and apoptosis. Aging is connected also with brain atrophy, enlargement of the ventricles, a decreased activity of enzyme, including NaATPase and higher membrane permeability. The brain regions most affected by atrophy are the hippocampus and frontal lobes (4). Moreover, brain ageing is also associated with significant changes in phospholipid fatty acid composition. In physiological conditions neurons have low capacity for cellular regeneration. Therefore, neurodegeneration results is irreversible and gradual progresses causing clinical symptoms such as motor and/or mental functioning (dementias). Moreover, neurons are highly vulnerable to oxidative/nitrosative stress due to their terminally differentiated morphology, metabolic and antioxidative dependence on surrounding astrocytes and glia. They are also very active and highly susceptible for oxygen and glucose reduction.

Astrocytes are multifunctional cells that constitute about 90% of CNS. They participating in metabolism, neuroprotection, neuroplasticity, neurotransmission and regulation of blood flow. The early stages of neurodegeneration are associated with the activation of common inflammatory pathways, involving microglia and astrocytes activation, and the release of pro-inflammatory cytokines and other inflammatory mediators that regulate astrocytic hypertrophy and proliferation (5). Persistent inflammation leads to reactive astrogliosis and increased expression of various genes, including glial fibrillary acidic protein (GFAP), a component of astrocytic filaments and commonly utilized marker of reactive astrogliosis.

Neural damage results in astrogliosis and up-regulation of GFAP in response astrocytes proliferate, migrate, and form glial scars that protect surrounding neuronal tissue from further damage. Reactive astrocytes can also produce several factors (cytokines, chemokines and neurotrophic factors) affecting brain injury (6). Microglia are characterized by different type of glial cell. They are the macrophage-derived resident immune cell that are maintain homeostasis in CNS microenvironment and activate in response of any changes. In physiological conditions, microglia mon-

itoring synaptic pruning, ultimately affecting neuronal connectivity and signaling.

The blood - brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) are the key structures in brain homeostasis. In neurodegenerative disorders, entrance of immune cells through the brain barriers is facilitated (7). The BBB is a selective physical barrier that composed from capillaries surrounded by perivascular macrophages and astrocytic endfeet. In this way astrocytes can directly modulate BBB function and regulate blood transport between the circulation and CNS parenchyma. Capillaries in CNS are in tight junctions that provide diffusion of small gaseous molecules such as NO_2 , O_2 and CO_2 and some lipophilic compounds but strictly reduce the entrance of large hydrophilic molecules including proteins. Neuronal membrane lipids are rich in polyunsaturated fatty acids (PUFA) side chains. PUFAs composed of eicosapentanoic (C20:5) and docosahexanoic (C22:6) acids are particularly vulnerable to free radical attack because of the double bonds, within the membrane allowing easy removal of hydrogen ions by ROS such as OH (8).

Antioxidant defense in CNS is rather low. Catalase (CAT) activity is significantly decreased in all brain regions. Furthermore, CNS contains less glutathione peroxidase (GPx), and vitamin E as compared to liver. However, the concentration of ascorbic acid, which can act as an antioxidant is elevated in both white and gray matter. Reports have showed that GSH is the major cellular antioxidant against ROS induced adverse effects, and its activity is closely related to cell survival. GSH is synthesized from glutamate, cysteine and glycine. Cysteine is the rate-limiting precursor of GSH synthesis. Neurons are considered to contain less glutathione than astroglial cells. *In vitro* studies have showed that in neuronal culture the GSH concentration range from 1-40 nmol/mg protein (9-11). Extracellular concentration of glutamate in CNS is normally low $< \mu\text{M}$. Several ROS are able to decrease glutamate uptake by glial cells and to inactivate glutamine synthetase, preventing conversion of glutamate to glutamine. This enzyme is inactivated in Alzheimer's disease. The early drop in cellular glutathione (GSH) levels observed together with oxidative glutamate toxicity is very similar to the changes seen *in vivo* within neurons responding to both acute and chronic injury.

4. OXIDATIVE/NITROSATIVE STRESS

Oxidative/nitrosative stress is strongly implicated in neurodegeneration pathophysiology and might provide a critical link between environmental factors such as heavy metals, viral infections, herbicides and genetic risk factors. However, a number of controversies begin to emerge in this field. It is suggested that, from one point of view, oxidative stress is an epiphenomenon of damaged and dying neurons, but, from

another, oxidative stress itself is the cause the of gradually damage leads to death of neurons. Mitochondria are the key organelles due to the fact that in the CNS 4×10^{12} ATP/minute is necessary to maintain neuronal intracellular ion homeostasis. Moreover, mitochondria are not only main ATP producer, but also a significant source of intracellular oxidants $-\text{H}_2\text{O}_2$ and $\cdot\text{NO}$. Longitudinal studies participants between 19–85 ages show a lower redox status as indicated by the linear oxidation of cysteine/cystine (Cys-SH/CysS-S) and GSH/GSSG (only after 45 years). This linear prooxidant shift indicates a chronic increase in oxidative events in lifespan.

5. NRF2-ARE PATHWAY

According function antioxidative proteins can be divided into 2 groups: the ROS-detoxifying enzymes, including superoxide dismutases (SODs), glutathione peroxidases (GPXs), and catalase. These enzymes in normal state are expressed in all cells by transcriptional regulation, that is the effect of function the other group of antioxidant proteins, transcription factors (TFs) such as peroxisome proliferator-activated receptor γ coactivator 1- α (PGC1 α) and nuclear factor erythroid-derived 2, like 2 (NRF2, also known as NFE2L2). PGC1 α and NRF2 are the main TFs that regulate whole antioxidant system. PGC1 α is a pleiotropic transcriptional coactivator. Cell regulates its endogenous antioxidant capacity is through activation of NRF2. Regulation occurs by binding to the antioxidant response element (ARE) in their regulatory regions. The ARE element is a cis-acting regulatory element that governs the expression of phase II detoxification enzymes. Expression of several detoxifying, cytoprotective, and antiinflammatory genes is boosted by NRF2. NRF2 acts via an "on-demand" mechanism. KEAP1 suppress this mechanism under physiological conditions, with nuclear accumulation upon stimulation by oxidation (12). Both groups of antioxidant genes have been proposed as therapeutic candidates, e.g., for neurodegenerative disorders NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage (13).

A multitude of genes involved in redox status, anti-inflammation and detoxification are transcribed by Nrf2-ARE pathway activation. These genes are known to be involved in cytoprotection from various oxidative insult and cellular injuries in numerous different tissues and organs including brain. Antioxidant enzyme systems regulated by Nrf2 include, but not limited to, redox regulation (superoxide dismutase (SOD), catalase (CAT), sulfaredoxin (Srx), thioredoxin (Trx), peroxiredoxin (Prdx) system), glutathione synthesis and metabolism (glutathione peroxidase (Gpx), glutathione reductase (GR), γ -glutamine cysteine ligase (GCL) and synthase (GCS)), quinone recycling (NAD(P)H quinone oxidoreductase (Nqo1)) and iron homeosta-

sis (heme oxygenase 1 (HO-1), Ferritin). Some anti-oxidant genes have more active roles than others in brain depending on the disease condition, cellular environment or cell type (12–14). In CNS, the Nrf2-ARE dependent gene expression is preferentially less activated in neurons compared to astrocytes (15–16). Recently research is focused at either astrocytic Nrf2 overexpression-mediated protection of neurons or modulating endogenous neuronal antioxidant capacity by small molecule Nrf2 activators or cell specific overexpression. Several disease specific studies involving Nrf2 activation/overexpression as a therapeutic strategy showed its ability to modulate the progression of major neurodegenerative disorders. Supplementary to its primary role in cytoprotection, Nrf2 is also linked to differentiation, proliferation, growth, apoptosis and it is thought that Nrf2 has evolved from an original role in haematopoiesis and the regulation of cell differentiation from early lineages (17).

6. NITRIC OXIDE AND PEROXYNITRITE

Nitric oxide (NO) has a very important role in the CNS. It can be produced by all brain cells including endothelial cells, neurons, glial cells (astrocytes, oligodendrocytes and microglia) by calmodulin Ca^{2+} /calmodulin dependent NOS-isoforms. In physiology NOS in neurons (nNOS) and endothelial cells (eNOS) produce very low amount of NO (nanomolar) in response to transient higher level of intracellular Ca^{2+} . NO is pleiotropic molecule responsible not only for cerebral blood flow but also for neuronal transmission, synaptic plasticity, modulation of neuroendocrine functions, memory formation and cognitive function. The production of NO is induced by excitatory stimuli amplifying toxicity in the CNS. Even slight induction of expression of iNOS in CNS cells results large amount of NO. NO can form RNS such as peroxynitrite, in combination with some forms of oxygen such as superoxide. Nitric oxide may take part in nitrosylation of proteins; however, peroxynitrite is a highly reactive nitrogen species that can nitrate tyrosine residues of proteins and change their function. Peroxynitrite formation has been implicated in AD, PD, HD, MS, ALS pathophysiology. Nitrotyrosine immunoreactivity has been found in early stages of all of these diseases in human autopsy samples as well as experimental animal models. Increased nitrite, nitrate and free nitrotyrosine has been found to be present in the cerebral spinal fluid (CSF) and proposed to be useful marker of neurodegeneration. Once formed peroxynitrite in CNS may exert its toxic effects by several mechanisms including lipid peroxidation, mitochondrial damage, protein nitration and oxidation, depletion of antioxidant reserves (especially glutathione), activation and inhibition many signaling pathways and DNA damage followed by the activation of nuclear enzyme PARP. Postmortem tissues from patients with AD, PD, HD, ALS or FA show oxidative damage in the affected brain regions (18).

7. CARBONYL STRESS

Advanced Glycated End Products (AGEs) are markers of carbonyl stress. Its accumulation is connected with increased level of sugars and reactive dicarbonyl compounds (19). AGEs are formed as a consequence of oxidative stress and in turn induce oxidative stress, amplifying damage in the CNS (20). AGE formation is irreversible process due to protease-resistant cross-linking of peptides and proteins, leading to protein deposition and amyloidosis. AGEs are the cause of cell damage by various mechanisms including direct neurotoxicity involving oxidative stress and apoptosis. Methylglyoxal (MG) has been suggested to be the main source of intracellular reactive carbonyl compounds involved in neurodegeneration (19).

8. REDOX THERAPIES IN NEURODEGENERATION

8.1. Ginkgo biloba

Ginkgo biloba is used *in vitro/vivo* studies as EGb761 (standardized extract of the leaves of the *G. biloba* tree) characterized by its main fractions, the flavonols glycosides 22–27%, terpene lactones (5–7%) and less than 5ppm ginkgolic acids. EGb761 is one of the commonly used herbal therapies for dementia and cognitive impairment. Potential neuroprotective properties of EGb761 were observed on molecular level (reduction of amyloid- β (A β) aggregation and A β toxicity). This polyvalent radical scavenger have the ability to optimized mitochondrial function as well as improve microperfusion. Moreover, this multitasking drug has very good safety and tolerance level. Several *in vitro* studies on rats models showed that EGb761 might strengthen neurotransmission especially glutamatergic (21), dopaminergic, and cholinergic systems. The systematic review and metaanalysis by Tan *et al.* show that in patients (n=2561) with dementia and cognitive impairment from 9 trials (placebo-controlled trials of 22–26 weeks duration) benefits from EGb761 therapy for stabilizing or slowing decline in cognition, function, behavior and clinical changes but this effects are mainly reached in the dose 240mg/day dose (21–22).

Results Yang *et al.* also suggest that Ginkgo might be effective as additional therapy in AD patients with cognitive impairment but without impact on its progression (23). However, the efficacy of *G. biloba* in AD is not clear. A 6 months regulatory trial carried out to obtain FDA marketing approval for EGb761 did not show efficacy for mild-to moderate AD. Furthermore, the Ginkgo Evaluation of memory trial demonstrated that *G. biloba* does not prevent dementia in elderly individuals with or without memory complaints or cognitive impairment and is not effective for prevention of AD (24). Few clinical trials have tried to examine the effectiveness of *G. biloba* in preventive AD. Among

these preventive trials is Guid Age - a multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 5 year study- conducted in 13 subgroups in France. The research has aimed to assess the efficacy of long term daily administration of 240 mg of a standardised *G. biloba* extract in lowering the risk of AD. The study was unsuccessful in showing the protective effects of *G. biloba* for the incidence of AD (25). Finally, in a meta-analysis review, the authors concluded that despite promising results, broad recommendations for the use of *G. biloba* in neuropsychiatric conditions, such as AD are still premature (26 27).

8.2. Coenzyme Q₁₀

Coenzyme Q₁₀ (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone) is a liposoluble compound also known as CoQ₁₀, vitamin Q₁₀, ubidecarenone or ubiquinone. It is obtained from the diet products or supplements, but is also produced endogenously about 3-5 mg per day in the mitochondria. The highest concentration of Co Q₁₀ in human tissues is at the age of twenty years, then gradually decreases. Co Q₁₀ is not classified as a vitamin or mineral, so it is no dietary reference value is recommended. CoQ₁₀ is one of the main cofactors involved in mitochondrial oxidative phosphorylation and also act as antioxidant (28 29). *In vitro* studies show that Co Q₁₀ easily crosses the BBB. The phase III trial of CoQ₁₀ in PD, QE3, is currently enrolling, and will shed some light on the question of a therapeutic range, with doses of 1,200 mg versus 2,400 mg of CoQ₁₀ (30). CoQ₁₀ levels are significantly decreased in mitochondria from SN neurons and platelets in PD patients, and levels of Co Q₁₀ have been shown to correlate with activity of complexes I and II/III (31). The nervous system is exposed to oxidative stress, and this may emphasize the role of Co Q₁₀ in the CNS especially in oxidative phosphorylation, metabolism of neurons with the constant and high energy demand of these cells. The property of CoQ₁₀ to be potent both as a pro-oxidant and an antioxidant suggests possible role as a modulator of cellular redox state in age related diseases. The mitochondrial inner membrane contains CoQ₁₀ and α -tocopherol demonstrated that Co Q₁₀ protects the cells from apoptosis, not only morphologically but also on molecular level (32). The first clinical studies concerning neuroprotective effects of Co Q₁₀ was reported in 1994 by Beal *et al.* This study showed that the intake of 1200 mg per day of Co Q₁₀ for sixteen months was associated with 44% less functional decline in PD patients (33). Another study in twenty-eight patients with PD also showed moderate improvement in symptoms with daily oral administration of 360 mg of CoQ₁₀ (34). It has been shown that CoQ₁₀ improves cognitive functions, regulates mitochondrial functions and facilitates the synthesis of ATP (35).

Coenzyme Q₁₀ is promising antioxidant especially in PD studies. In-vitro studies using fibroblasts

from PD patients showed that exogenously administered CoQ₁₀ restore electron transport chain activity. As a lipophilic antioxidant, CoQ₁₀ is capable of scavenging radicals within membranes and in the cytosol and plasma when bound to lipoproteins. Preliminary data from a phase I study suggested that that exogenously administered CoQ₁₀ may retard disease progression in PD. Platelet CoQ₁₀ redox ratios have been shown to be significantly decreased in PD patients (36). CoQ₁₀ supplementation also resulted in decreased serum levels of MMP-9 as compared to the placebo group. However, CoQ₁₀ supplementation did not change the IL-4 and TGF- β levels. CoQ₁₀ supplementation at a dosage of 500 mg appears to decrease the inflammatory markers (TNF- α , IL-6, and MMP-9) in the group of 24 MS patients. The intervention was administered for 12 weeks (37).

8.3. Selenium

Selenium is an essential micronutrient with very narrow recommended dietary range. The RDA for selenium is approximately 55 μ g/day and selenium can be obtained from supplements and dietary intake. Selenium, in the form of selenocysteine, is a constituent of 25 classes of selenoproteins, including GPxs, selenoproteins P, W, and R, and thioredoxins (TrxR). Moreover, selenium, could act as immunomodulator, antioxidant and anti-inflammatory factor. Approximately 60% of selenium in plasma is present as selenoprotein P (38 39) This protein differs from other selenoproteins in that it incorporates up to 10 Se atoms per molecule in the form of selenocysteine as opposed to the single selenocysteine incorporated in other selenoproteins. Most studies are found the role in Alzheimer's and cognitive impairment (40-42).

Another study in France evaluated selenium levels in 1389 elderly patients (60–71 years) over time and found that short-term decline in selenium levels had no effect on cognitive function but longitudinal, selenium deficiency may contribute to reduced neurological cognitive function. Additionally, Aguilar *et al.* have reviewed the role of selenium in multiple sclerosis, Alzheimer's and Parkinson's disease (43). Changes in selenium concentration in diseased brains with Alzheimer's disease and multiple sclerosis were reported, but no change in selenium levels were observed in studies with Parkinson's disease (44-48).

Selenoprotein P levels can be maintained in the CNS independent of plasma selenium level (38). However, genetic ablation of selenoprotein P results in reduced, but it is compensated by other selenoproteins and supporting the hypothesis that basal selenium levels are essential for the brain and have a priority. Reduced dietary selenium can have significant effects on levels of selenoproteins involved in oxidative stress, such as glutathione peroxidases, thioredoxin reduc-

Table 1. The potential of nutraceuticals and pharmacotherapies with redox activity in neurodegenerative disorders

Pharmaceuticals	Standardized extract (compound)	Dosage	Therapeutic strategy	BBB	Disorder	Function and role <i>In vitro</i> */ <i>vivo</i>	Ref.
Ginko biloba	EGb761	240-360 mg/day	Cognition Memory Attention		Alzheimer's Disease	reduce amyloid (A β) aggregation and A β toxicity an inhibitor of the platelet activating factor (PAF) receptor*	[1,2,3]
Ubidecarenone	Coenzyme Q10	produced endogenously 3–5 mg per day 30-200mg per day	Cognition	+	Parkinson disease Multiple sclerosis	protects the cells from apoptosis; decrease the inflammatory markers (TNF- α , IL-6, and MMP-9)	[4] [5]
Selenium	Selenoproteins glutathione peroxidase (GPx), thioredoxin reductase (TrxR), and selenoprotein P (SeP).	55 micrograms (mcg)/day	selenium deficiency may contribute to reduced neurological cognitive function		Alzheimer's disease Parkinson Disease Multiple sclerosis	Seleno-L-methionine protects against amyloid (A β) and iron/ hydrogen peroxide-mediated neuron death*; Protection of hippocampal neurons *	[6] [5]
Curcumin	Tumeric	Standardized powder (curcumin): 400 - 600 mg, 3 times per day Fluid extract (1:1) 30 - 90 drops a day Tincture (1:2): 15 - 30 drops, 4 times per day	Cognition	+	Alzheimer's disease Parkinson Disease	reduce amyloid (A β) levels and plaque burden* detoxification of ROS and peroxynitrite; Increase GSH synthesis*; suppresses the activation of transcription factor NF-kB*	[20]
Cannabinoids	Dronabinol (2.5mg delta-9-tetrahydrocannabinol (delta-9-THC) Nabilone CBD (cannabidiol) Nabiximols Ratio of 2.7mg Δ 9-THC, 2.5 mg	2.5-20mg/day 100 mg (0.03mg/kg) 65-120mg/day	Cognition Memory Sympathomimetic activity; Tremor and spasticity; Dystonia and dyskinesia Neuropathic pain		Parkinson Disease Alzheimer's disease ALS Multiple sclerosis	Antioxidant activity; Decreases proinflammatory cytokines (TNF- α , IL-1 β), and NFkB activity; protected dopaminergic neurons* Increase trophic factors and anti-inflammatory cytokines (IL-10). Prevents excitotoxicity by reducing glutamate release and signaling; Promotes oligodendrocytes survival, reducing demyelination and apoptosis	[9-13] [16,17] [12]
Melatonin	N-acetyl-5-methoxytryptamine	0.1-20mg/day	Quality of sleep Cognition	+	Multiple sclerosis Alzheimer's disease	Increase of SOD, GPx and decrease of MDA in erythrocytes; increased hippocampal synaptic density and the number of excitatory synapses, decrease the number of inhibitory synapses, and upregulated pre- and postsynaptic proteins	[15] [16,18,19]
Omega-3 fatty acid	EPA (Eicosapentaenoic acid) DHA. (docosahexaenoic acid)	250-4000 mg/day EPA/DHA 1 g contains 180 mg (EPA) / 120 mg (DHA).	Cognition		Alzheimer's disease	decreases NaTPase activity, increase the levels of hippocampal BDNF*	[13,14]

tases and methionine sulfoxide reductases. Selenium, through the incorporation into selenoproteins, provides protection from reactive oxygen species (ROS)-induced cell damage and neuroplasticity. Selenoprotein P deficiency results in subtle spatial learning deficits and severe synaptic plasticity defects. It is difficult to discern whether this is due to selenoprotein P itself, or the loss of selenium transport to the CNS (49). Exposures to high levels of environmental selenium have been associated with motor neuron disease in both animals and humans and high levels of selenite have been identified in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS).

8.4. Curcumin

Curcumin (diferuloylmethane) is a component of turmeric, natural plant polyphenol derived from the spice. It is widely used as a food flavoring and coloring agent (e.g., in curry). Curcumin was demonstrated to exert pleiotropic cellular effects, which include antioxidant activity and direct detoxification of ROS and peroxynitrite as well as prevent toxicity associated with pathological protein aggregation (50). Hence, the neuroprotective efficacy of curcumin has been assessed in various diseases of mitochondrial metal dysfunction including AD, PD and stroke models. Moreover, curcumin is able to cross the BBB. Treatment of astrocytes with curcumin induced the cytoprotective proteins HO-1, NQO1, and GST and provided protection against the damaging effects of glucose oxidase-mediated toxicity. Further, curcumin was reported to bind to amyloid plaques, and to reduce amyloid levels and plaque burden in aged (51–52). Its rapid elimination from the brain has resulted in several drug design approaches to improve bioavailability. Curcumin and its derivatives have been tested in numerous cell and animal models of PD. Treatment of N27 dopaminergic neurons with a glutamic acid substituted curcumin derivative-induced neuroprotection involving increased GSH synthesis and a reduction in oxidative stress, lipid peroxidation and H₂O₂ production (53). N27 neurons were also protected from MPP⁺-induced cytotoxicity by Di-glutamoyl curcumin (54). Furthermore, curcumin improved survival of dopaminergic neurons in the SN in MPTP-lesioned C57BL/6 mice via JNK-dependent inhibition of mitochondrial swelling and cytochrome c release (55). Curcumin-fed rats that had been 6-OHDA-lesioned displayed elevated striatal dopamine levels and had a decreased number of iron-positive cells in the SN, suggesting that curcumin-mediated iron chelation may be responsible for protection of dopaminergic neurons from Fenton chemistry-dependent neurodegeneration (56–57). Curcumin has also been reported to reduce Huntington accumulation and improve rearing behaviour in HD CAG140 knock-in mice (58). Similar to Cull(atm), the cellular mechanism of action of curcumin involves activation of kinase signalling pathways. Pharmacological inhibition of the Akt, but not MAPK, pathways decreased cur-

cumin-stimulated Nrf2 activation and Nrf2-dependent gene expression in primary rat cultured cortical neurons (59), including both the PD-associated α -synuclein and ALS-associated TDP-43 (60–63).

8.5. Omega-3 fatty acid

Omega-3 fatty acid (Docosahexaenoic Acid) have been shown to influence a number of membrane proteins, such as receptors, ion channels and enzymes. Furthermore, they can also modulate dopaminergic, serotonergic, cholinergic neurotransmission and regulate signal transduction pathways. Chronic omega-3 PUFA deficiency significantly decreases NaTPase activity in rat brain (64). DHA is the most complex form of Omega-3 and is difficult to include in our diet as only few foods contain a significant amount. Other forms of Omega-3 are inefficiently converted to DHA in our body. Omega-3 DHA is taken up directly into cell membranes, whereas plant-derived fatty acids are not. Fats account for over 50% of the brain and Omega-3 DHA represents 30% of brain matter. The highest concentration of Omega-3 DHA in the human body is in the retina where it helps to reduce inflammation which is almost unavoidable event in most of the neurodegenerative diseases.

With aging and in AD patients the level of DHA is significantly lower in blood plasma and brain (65). This not only could be due to lower dietary intake of omega-3 fatty acids, but it also could be connected with increased oxidation of PUFA (66).

Dietary supplementation of DHA has been shown to increase the levels of hippocampal BDNF (67). Calon and colleagues (68) found that a diet rich in DHA activates Ca²⁺/calmodulin-dependent protein kinase (CaMKII). This signalling cascade is critical for learning and memory and plays a crucial role in induction and maintenance of long-term potentiation in hippocampus. In summary, results from controlled studies conducted over the last 10 years suggest that nutritional intervention with omega-3 fatty acids is beneficial only in the earlier stages of cognitive impairment.

AD is strongly correlated with lower level of omega-3 PUFA both in brain and peripheral tissues. Decreased DHA content in serum phosphatidylcholine has been suggested as a significant risk factor for developing AD.

8.6. Melatonin (MLT)

MLT is well known as a potent neuroprotectant and effective antioxidant. MLT is able to pass easily through the blood brain barrier and enters into all cells with its lipophilic and hydrophilic nature. MLT production gradually decline with the aging and numerous studies have associated this decrease with

higher induction of oxidative stress and age-associated degenerative changes. Melatonin increases enzymatic antioxidative defensive systems, including SOD and GPx as well as the levels of glutathione and the decreased pro-oxidant enzymes activity, especially 5- and 12-lipo-oxygenase and nitric oxide (NO) synthases. The majority of endogenous melatonin is directly released from the pineal gland to the cerebrospinal fluid (CSF). Up to 20 folds lower fraction is released into the capillary blood where it is distributed to all tissues. Additionally, recent studies showed that melatonin has potential to effectively bind and inactivate endogenous iron. Thus it can suppress the Fenton reaction and in the consequence decrease overproduction of ROS (33). Receptor-independent effects of melatonin are based on its direct binding to calmodulin, thus causing inhibition of Ca^{2+} /calmodulin-dependent kinase II (49) and Ca^{2+} -dependent membrane translocation of protein kinase C (50). Melatonin can also prevent specifically the activation of the pro-inflammatory enzymes COX-2 and iNOS in glioma cells, thus indicating an anti-inflammatory action. Importantly, melatonin does not alter COX-1 protein level.

To determine the action of MLT in the reduction of oxidative stress in MS, lipid peroxidation and activities of main antioxidative enzymes in the red blood cells (RBCs) from group of MS patients with secondary progressive clinical course were studied. The patients were supplemented with MLT (10 mg daily/30 days). MLT caused statistically significant increase of SOD, GPx and decrease of MDA in erythrocytes of MS patients. The results showed that use of MLT in MS patients could be taken into account, especially in progressive form of MS (69). Last studies report that addition of 30 mol% MLT to the anionic membranes significantly reduced the membrane-embedded $\text{A}\beta$ state (70).

8.7. Cannabinoid

The cannabinoid system presents a promising target for the treatment neurodegenerative disorders. CB1 and CB2 are two major cannabinoid receptors. Those receptors have been cloned and several endogenous cannabinoids were identified along with their synthetic and degradative pathways. ECBs are located not only in the brain, but also in the periphery in humans and animals. ECBs are produced by cultured neurons, microglia and astrocytes. Low levels CB1 receptors have found on mitochondrial membrane suggesting a direct relationship between CB1 receptor and mitochondrial functions in the brain. The phenolic ring moieties in cannabinoids display antioxidant activity and guard against glutamate-induced neurotoxicity in a cellular model. (71).

The cannabis resin and flowers was isolated in 1964 as Δ^9 -tetrahydrocannabinol (Δ^9 -THC). Since that time, numerous non-psychoactive cannabinoids

have been identified, such as cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), Δ^9 -tetrahydrocannabinol (Δ^9 -THCV) and cannabidivarin (CBDV). The most widely studied phytocannabinoid is Δ^9 -THC. Sativex® is used to alleviate spasticity in adult multiple sclerosis (MS) patients which haven't respond to other drugs during an initial trial period of therapy. Several side effects associated with cannabinoid administration were observed: euphoria, somnolence, and tiredness, but these did not warrant discontinuation of therapy. Cannabinoids might represent low-cost and safe therapy. Currently, the endocannabinoid system is a novel therapy for AD patients. due to its potent neuroprotective, anti-inflammatory, and neurotrophic properties. The synthetic phytocannabinoid, HU-211, has been shown to act as a stereoselective inhibitor of N-methyl-D-aspartate (NMDA) receptors and thereby protect rat forebrain cultures and cortical neuronal cultures from excitotoxicity (72-74). Cannabinoids can also modulate the brain-derived neurotrophic factor (BDNF) to amplify neuroprotection against excitotoxicity (75). In a mouse model of AD, which received an intrahippocampal administration of $\text{A}\beta$ 1-42, CBD prevented reactive gliosis and the release of proinflammatory mediators (76). CBD has also been shown to dampen $\text{A}\beta$ -induced GSK-3 β activation thereby preventing tau hyperphosphorylation and the subsequent formation of neurofibrillary tangles (77).

8.8. Vitamin E and C

Vitamin E and C Prevention of neuronal death can be also achieved by functional foods performing neuroprotective effects through antioxidant actions. A higher intake of vegetables, fruits, and seeds rich in vitamin C, carotenoids and vitamin E is positively associated with better cognitive function and a decreased risk of dementia in the elderly. The reduction the prevalence of AD in aged people can be associated with the combination of vitamin E and vitamin C intake (78 79).

9. OTHER REDOX THERAPIES

9.1. Physical Exercise

Existing hypotheses suggest that physical exercise represents a potential adjunctive treatment for cognitive impairment. This may help to delay the onset of neurodegenerative processes. Exercise appears to stimulate neurogenesis, enhance neuronal survival, increase resistance to brain insults and increase synaptic plasticity. In individuals 65 years and older, physical activity has been shown to protect against the continuous development of AD. In addition, regular moderate physical exercise can positively influence depressive symptoms in AD patients (80 81). In the Canadian Study of Health and Aging, individuals aged 65 years or older who were engaged in regular physical activities had a 50% reduced risk of developing AD (82 83).

10. NEURODEGENERATIVE DISORDERS AND REDOX THERAPIES

10.1. Parkinson disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease characterized by progressive and massive loss of dopaminergic neurons in the midbrain, which leads to several motor symptoms. PD occurs worldwide, with equal incidence in both males and females. The prevalence increases exponentially with age between 65 and 90 years. The mean age of onset is about 65 years. However, 5-10% of people who develop PD, experience symptoms before the age of 40 (young onset). Motor symptoms of PD involve bradykinesia, rigidity, tremor and postural instability. PD patients also suffer from non-motor symptoms such as disturbances of olfaction, vision, sleep and of the autonomic nervous system. Moreover many PD patients present neuropsychiatric symptoms such as anxiety, fatigue, apathy, anhedonia, depression and dementia. Symptoms of PD start to appear when 50-60% of SNc dopaminergic neurons and 70-80% of striatal nerve terminals are lost. Research data have clearly indicated that during PD, SN dopaminergic neurons are subject to oxidative and nitrosative stress, and mitochondrial dysfunction, proteasome inhibition and protein aggregation. In PD ROS contributes to BBB dysfunction. Moreover, metalloproteinase-9 (MMP-9) activity, involved in degrading the basal lamina was increased by oxidative stress, whilst antioxidant treatment of brain ECs prevented MMP-9-induced TJ disassembly (84).

Moreover, brains from PD patients show evidence of elevated oxidative damage to DNA (85), lipid peroxidation and oxidative modification of proteins (86), decreased levels of reduced glutathione (GSH) and increased monoamineoxidase (MAO) activity (87 88), that indicate reduced antioxidant defense mechanisms. Dopamine oxidation by MAO leads to the formation of ROS (87) and, if not effectively detoxified by glutathione, hydrogen peroxide might potentially induce the generation of highly reactive hydroxyl radicals in the presence of excess iron via the Fenton reaction. Lewy bodies, considered cytopathologic markers of parkinsonism, comprise abnormal arrangements of tubulin and microtubule-associated proteins, MAP1 and MAP2. Melatonin effectively promotes cytoskeletal rearrangements and was assumed to have a potential therapeutic value in the treatment of parkinsonism, and, perhaps, generally in dementias with Lewy bodies (89 90).

Drug treatment provides symptomatic relief, reduce disability, maintain independent functioning and thus improving quality of life of the patient. Currently first line standard treatment includes L-dopa, dopaminergic agonists, monoamine oxidase B inhibitors

and drug combinations. Other medications include catechol-O-methyltransferase, anticholinergic agents and amantadine (91 92). Evidence suggests that elements of the cannabinoid system may play a neuroprotective role in PD via inhibition of oxidative and inflammatory processes.

10.2. Alzheimer Disease

The development of Alzheimer's disease (AD) is closely connected with deposition of amyloid beta plaques (AB) and neurofibrillary tangles in tissue brain (93). There are more evidence that one of the main cause of AD is closely associated with aggregation these specific protein for neurodegenerative diseases especially in the neocortex which is affiliated with pathological interactions metal ions such as Zn, Cu as well as Fe in this area of humans' brain (94). During the aging process tissue brain accumulates the metal ions, but the presence of antioxidants are responsible for providing the oxidative homeostasis. However alterations in oxidative metabolism, which are one of the hallmark in AD, indicate that oxidative stress plays the crucial role in AD pathogenesis (95).

AB is derived from amyloid β protein precursor (APP) during the cleavage of the APP by enzyme BACE1 (96 97). APP molecules include metal binding domain for copper and zinc, which are located in the N-terminal region and are similar to the family of proteins known as copper chaperons whose main hallmark is affinity for reducing ions Cu^{2+} *in vitro*. The zinc binding domain is described as the structural domain, but the vital role of copper binding provides the ability to reduce molecule of Cu^{2+} to Cu^{+} and moreover promotes neurotoxicity of copper as well as disturb the metal homeostasis in neuronal cells. The conducted research indicate that APP knockout mice was characterized by increasing levels of Cu, and mice with overexpression of APP were characterized by decreasing levels of Cu mainly in the brain cortex. Decreased APP may contribute to increase the level of copper which as a result leads to AB aggregation and moreover releasing the free radical forms of AB. Imbalance in copper homeostasis in humans' brain could lead to initiation and progression the AD, since the cortex is the area of brain primarily affected in the AD (95 98 99).

Furthermore, AB plaques might also bind metal ions *in vitro* which plays the vital role in increasing its levels in the neocortex and leads to significant accumulation of AB molecules among the neurons in brains of individuals with AD, for instance zinc ions markedly increase precipitation of AB plaques (100). It has been also reported that AB plaques may reduce Cu^{2+} to Cu^{+} which generates the H_2O_2 in neurons cell and moreover it is associated with neurotoxicity of AB plaques caused by Cu^{2+} ions (101).

Recent investigations based on metal imbalance in tissue AD brain present a new point of view on therapeutic strategy for AD. The potential therapeutic target in AD are chelating agents which has the potential to prevent and what is the most important reverse AB deposition in the AD brains. However, one of the problems for this approach was connected with chelators bioavailability and its toxicity, but recent research indicate that for instance covalent conjugation iron chelators with nanoparticle may facilitate their transport by blood-brain-barrier and reduce their toxicity (102 103). Moreover, conjugated nanoparticles with chelators not altering their ability to bind metals. The novel therapy based on deliver chelators to the AB plaques in AD brains and transport the complex metal-chelators from the brain tissue which may play the crucial role during the prevention of inducing the reactive oxygen species by AB which results in neuronal loss during the progression of AD (102 104).

The key neuropathological hallmarks of AD include deposition of amyloid beta (A β) plaques and the presence of neurofibrillary tangles composed of the hyperphosphorylated form of the microtubule associated protein, tau. Therapeutic approaches to AD are symptomatic relief with low efficacy. Two classes of drugs currently approved for use by the FDA include the acetylcholinesterase inhibitors, namely donepezil, galantamine and rivastigmine and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine. Acetylcholinesterase inhibitors are indicated for patients with mild to moderate symptoms while memantine is recommended for moderate to severe cases of AD. Currently, disease modifying drugs (DMD) are being pursued against amyloid deposition, tau deposition, inflammation and oxidative stress (105). The postmortem histopathological analysis confirmed an elevated lipid peroxidation and DNA oxidation and protein reorganization in the brain cortex in the brains of AD patients with typical changes in cytoskeletal architecture. The antioxidative protection against A-beta of melatonin has been confirmed by Pappolla *et al.*, which showed that co-incubation of both murine neuroblastoma (N2a) and pheochromocytoma (PC12) cells with A-beta-peptides and melatonin greatly reduced the degree of A-beta-induced lipid peroxidation, thus greatly increasing the survival of the cells (102). *In vitro* studies demonstrated that melatonin could protect from neurofilaments hyperphosphorylation changes and accumulation induced by calyculin A (CA), through not only its antioxidant effect but also its direct regulatory effect on the activities of protein kinases and protein phosphatases. The melatonin concentration in CSF is decreased that gradually progresses in AD. Moreover, melatonin levels both in CSF and in postmortem human pineal gland are already reduced in early stage of AD with no cognitive impairment (106-109). Therefore, CSF melatonin level has been suggested as an early marker for the detection of AD. With regard to

the anti-inflammatory effects of melatonin, the most important feature is its inhibition of mitochondrial iNOS expression (110 111) Another approach being investigated is targeting the mitochondria which are involved in the pathology of AD. As such MitoQ, an orally active antioxidant currently in development by Antipodean Pharmaceuticals Inc, is now undergoing Phase II clinical trials for the potential treatment of neurodegenerative diseases. MitoQ which comprises of a ubiquinone moiety is believed to be a promising antioxidant candidate for treating AD patients (112).

10.3. Glaucoma

Glaucoma is the second most common cause of blindness in the world (113). The main factor for glaucoma is elevated intraocular pressure (IOP). Treatment consists in reducing the IOP, and this is so far the only available therapy, although it is known that this is not the only factor causing this damage of *retinal ganglion cells (RGC) and their axons* resulting in loss of vision. Glaucoma is now recognized like a multifactorial neurodegenerative disorder (114 115). In 1990 Weinreb and Levin suggested that neuroprotection of glaucomatous optic nerve should be an additional therapy to traditional intraocular lowering-pressure treatment (116 117).

The goal of neuroprotective treatment is to reduce or slow damage to RGC (118 119). We have many clinical studies that show the influence of drugs to prevent damage to the RGC. The largest neuroprotection in glaucoma clinical trial investigated the efficacy of memantine an NMDA receptor antagonist (*Irvine, CA, USA; "Memantine in Patients With Chronic Glaucoma", clinicaltrials.gov NCT00168350*). Despite good results in glaucoma preclinical studies, Phase 3 of the study did not confirm these results. Although memantine can prevent neuronal necrosis but did not affect apoptosis of these cells caused by oxidative stress. Therefore, just as in Alzheimer's disease, attempts to add vitamin D to memantine, which has an antioxidative and anti-inflammatory effect. For this purpose, new clinical trial started in France (120). Brimonidine tartrate 0.2.% ophthalmic solution (Alphagan, Allergan), a highly selective alpha 2-adrenergic agonist used in the management of ocular hypertension and glaucoma has also neuroprotective effect demonstrated in animal studies (121). However, due to the large number of patients (55%) which was missing in a 4-year follow-up, you can not refer to the results of this clinical trial.

Ginkgo biloba disturbed ocular microcirculation, oxidative stress, impairment of mitochondrial function in the retinal ganglion cells and could have potentially neuroprotective effect in glaucomatous patients. Because of the possibility of complications, such as bleeding, headache, and the fact that there is one clinical trial evaluating its effectiveness in glauco-

ma, it is not a drug commonly used (122-123). Another antioxidant such as α -lipoic acid, 17 β -estradiol containing eye drops and estrogens was also shown neuroprotective effects in preclinical studies (124-126). Some clinical trials which tested antioxidants (α -tocopherol, Ginkgo biloba and an antioxidant formula) was in Phase 3 study but the results are still not known. Calcium channel blockers relieve pressure in eyes and increase blood flow in patients with open-angle glaucoma (127-128). Calcium channel blocker such as Flurizine (129), Nimodipine (130), Nilvadipine (131) and Lomerizine (132) demonstrate neuroprotective effect in many experimental and clinical studies. Secreted protein brain-derived neurotrophic factor (BDNF) have been studied and evaluated in multiple clinical trials. It showed a beneficial neuroprotective effect of retinal ganglion cells, such as: improved survival, protection of RGCs (133-134). In conclusion glaucoma is multifactorial neurodegenerative disorder. Recent clinical trials show that neuroprotection in glaucoma treatment (especially antioxidative therapy) can be effective and widely used in the future. Despite this, further clinical trials and approved widely available drugs are needed.

10.4. Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease, affecting both the first and second motoneuron. The main feature of ALS progression is degeneration of motor neurons associated with massive demyelination in the anterior horn of the spinal cord. The etiology is not entirely understood. There are three major processes suggested in ALS pathophysiology: (a) mutations of the superoxide dismutase 1 (SOD1) gene, causing a toxic gain of function with enhanced reactivity towards abnormal substrates (tyrosine nitration), along with an impaired ability to bind zinc leading to a reduced antioxidant capacity; (b) mutations in neurofilament genes and oxidative modifications or hyperphosphorylation of cytoskeletal proteins leading to selective motor axon degeneration; (c) excitotoxicity caused by increased cerebrospinal fluid glutamate levels together with a loss of excitatory amino acid transporters (170). In SOD1(G93A)-transgenic mice, high-dose oral melatonin delayed disease progression and extended survival. In a clinical safety study, chronic high-dose (300 mg/day) rectal melatonin was well tolerated during an observation period of up to 2 years (135).

10.5. Multiple sclerosis

Multiple sclerosis (MS) is a chronic progressive heterogeneous disease of CNS leading to focal plaques of demyelination in both white and grey matter, together with profound axonal and neuronal degeneration (46). The main reason of disability progression is axonal loss. Recent studies, suggest that oxidative damage is one of the main biochemical pro-

cess in MS pathogenesis. The number of T cells and macrophages shows statistically significant correlation with the level of oxidation of DNA and lipids (136).

Iron is also discussed as a factor promoting oxidative injury in degenerating oligodendrocytes or myelin during demyelination (137). There are four main clinical types of MS relapsing-remitting (RR), secondary-progressive SP, primary-progressive (PP), and relapsing-progressive (RP). Recent studies pointed out that melatonin genes pathway seems to be involved in MS progression. These data showing the association of polymorphisms in the TPH2 and MTNR1B genes with the progressive subtypes of MS and disability suggest dysregulation in melatonin pathway. Melatonin abolishes destructive cuprizone effects in the corpus callosum by decreasing oxidative stress, restoring mitochondrial respiratory enzyme activity and fusion and fission processes as well as decreasing intra-axonal mitochondria accumulation. Protective effects of melatonin against mitochondrial injury in a mouse model of MS were observed.

Schwarz *et al.* analyzed wide range of complementary and alternative medicine using: diet modification (41%), omega-3 fatty acids (37%), vitamin D (28%), Vitamin E (28%) and vitamin C (28%) homeopathy (26%) and selenium (24%). Majority out of 1573 MS patients (69%) were satisfied with the effects of complementary treatment. Compared with conventional therapy complementary and alternative therapies rarely showed side-effects (9%vs59%) (138).

Currently, very promising results of MS patients are connected with Fumaric acid esters (FAE) therapy used in psoriasis treatment for over 30 years. This drug has been involved in altering response to oxidative stress via nuclear-related factor E2-related factor 2 (Nrf2). The Nrf2 pathway increases expression of antioxidative proteins and in this way provides neuroprotection and homeostasis of immune system.

Moreover, fumaric acid esters are oral therapy what is very rare way of drug application in MS (139-140). The results of randomized, placebo-controlled phase II study indicate significant positive effects of FAE on diverse MRI parameters in MS patients. It has been shown in clinical studies in psoriasis that FAE caused a decrease of peripheral CD4+ and CD8+ T-lymphocytes by stimulation of apoptotic processes (141). Oral dimethyl fumarate (DMF, Tecfidera) was approved for treatment patients with RRMS in 2013. DMF has not only anti-inflammatory but also neuroprotective properties. Neuroprotection is mediated by activation of the nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) antioxidant pathway. Nrf2 nuclear translocation was shown in neurons, oligodendrocytes, and astrocytes in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, as

well as in astrocytes *in vitro* after DMF application. Nrf2 is also might induced as a natural response in MS brains, as has been shown in autopsy studies (140). *In vitro* studies showed dimethylfumarate ester's inhibitory effect in human endothelial cells on nuclear factor kappa B (NF- κ B)-dependent transcription of tumor necrosis factor- α (TNF- α) induced genes. Experimental studies of EAE demyelinated CNS showed distinct neuroprotection myelin and axons. Molecular reports reports that these processes are dependent on the antioxidative mechanism thorough transcription factor Nrf-2 stimulation. A phase II clinical trial in RRMS patients with dimethylfumarate presented a substantial decrease in the number of gadolinium advancing lesions after 24 weeks (84, 85). This positive immunomodulation seems to be similar to first line of DMD that are basic treatment of RRMS in the early phase. Many years of treatment in psoriasis showed safety profile of dimethylfumarate (DMF) formula BG12. Treatments targeting oxidative injury or protecting mitochondria were shown to be beneficial (142-143).

11. CONCLUSIONS

The therapeutic approaches presented in this review show a large body of promising therapies in treating neurodegenerative diseases. The main benefit from using redox therapies is the protective action on CNS cells function by antioxidant mechanisms that prevent toxic processes. The evidence from both *in vitro/vivo* models reported that ROS/RNS damage occurs in neurodegenerative disease. Redox therapies appear as a very useful way to alleviate typical clinical symptoms including cognitive impairment, spasticity, pain and others. Although, antioxidant therapies has been rather ineffective in clinical trials in slowing down the disease progression. There may be several explanations underlying these findings, including the diverse mechanisms of pro-oxidant action in disease pathology and the advanced nature of the oxidative damage at the time of clinical presentation. However, recently several medications with redox properties has been approved for the treatment CNS disorders including cannabinoids or BG12 (Tecfidera) an oral drug composed of dimethyl fumarate (DMF) that of RRMS. The clinical results suggest that an activation of nuclear translocation of Nrf2 after fumarate is main neuroprotective pathway. The other problems with providing trials are plenty of formulas and doses used in studies targeting redox therapies that make comparative analysis difficult. Moreover, there is also the placebo effect, which has been reported to be as high as 50%, interferes with proof of efficacy, although the ability to recognize treatment. In addition, the need to use many subjective measures such as patient-driven symptom rating scales is the key point in this field. Therefore, it is necessary to conduct randomized controlled studies to determine the efficacy of clinical use.

12. REFERENCES

1. IpPS, TsimKW, ChanK, BauerR.: Application of complementary and alternative medicine on neurodegenerative disorders: current status and future prospects. *Evidence-based complementary and alternative medicine* : eCAM 2012;2012:930908 (2012)
DOI:10.1155/2012/930908
2. Nguyen, L., Lucke-Wold, B. P., Mookerjee, S. A., Cavendish, J. Z., Robson, M. J., Scandinaro, A. L., Matsumoto, R. R.: Role of sigma-1 receptors in neurodegenerative diseases. *Journal of pharmacological sciences* 127(1):17-29 (2015)
DOI:10.1016/j.jphs.2014.12.005
3. Prolla TA, Mattson MP.: Molecular mechanisms of brain aging and neurodegenerative disorders: lessons from dietary restriction. *Trends in neurosciences* 24(11 Suppl):S21-31 (2001)
DOI:10.1016/S0166-2236(00)01957-3
4. Anderton BH.: Ageing of the brain. *Mechanisms of ageing and development* 123(7):811-7 (2002)
DOI:10.1016/S0047-6374(01)00426-2
5. Colangelo AM, Alberghina L, Papa M.: Astroglialosis as a therapeutic target for neurodegenerative diseases. *Neuroscience letters*565:59-64 (2014)
DOI:10.1016/j.neulet.2014.01.014
6. Kim JH, Min KJ, Seol W, Jou I, Joe EH.: Astrocytes in injury states rapidly produce anti-inflammatory factors and attenuate microglial inflammatory responses. *Journal of neurochemistry* 115(5):1161-71 (2010)
DOI:10.1111/j.1471-4159.2010.07004.x
7. Marques F, Sousa JC, Sousa N, Palha JA.: Blood-brain-barriers in aging and in Alzheimer's disease. *Molecular neurodegeneration* 8:38 (2013)
DOI:10.1186/1750-1326-8-38
8. Hawkins RA, Sangster K, Arends MJ.: Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism. *The Journal of pathology* 185(1):61-70 (1998)
DOI:10.1002/(SICI)1096-9896(199805)185:1%3C61::AID-PATH49%3E3.0.CO;2-8

9. Raps SP, Lai JC, Hertz L, Cooper AJ.: Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. *Brain research* 493(2):398-401 (1989)
DOI:10.1016/0006-8993(89)91178-5
10. Fernandez-Fernandez S, Almeida A, Bolanos JP.: Antioxidant and bioenergetic coupling between neurons and astrocytes. *The Biochemical journal* 443(1):3-11 (2012)
DOI:10.1042/BJ20111943
11. Dringen R, Gutterer JM, Hirrlinger J.: Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. *European journal of biochemistry* 267(16):4912-6 (2000)
DOI:10.1046/j.1432-1327.2000.01597.x
12. Williamson TP, Johnson DA, Johnson JA.: Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. *Neurotoxicology* 33(3):272-9 (2012)
DOI:10.1016/j.neuro.2012.01.015
13. Xiong W, MacColl Garfinkel AE, Li Y, Benowitz LI, Cepko CL.: NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage. *The Journal of clinical investigation* 125(4):1433-45 (2015)
DOI:10.1172/JCI179735
14. Wang Z, Ma C, Meng CJ, Zhu GQ, Sun XB, Huo L, Zhang J, Liu HX, He WC, Shen XM, Shu Z, Chen G.: Melatonin activates the Nrf2-ARE pathway when it protects against early brain injury in a subarachnoid hemorrhage model. *Journal of pineal research* 53(2):129-37 (2012)
DOI:10.1111/j.1600-079X.2012.00978.x
15. Kraft AD, Johnson DA, Johnson JA.: Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 24(5):1101-12 (2004)
DOI:10.1523/JNEUROSCI.3817-03.2004
16. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH: Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. *The Journal of neuroscience: the official journal of the Society for Neuroscience* 23(8):3394-406 (2003)
17. Bryan HK, Olayanju A, Goldring CE, Park BK.: The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. *Biochemical pharmacology* 85(6):705-17 (2013)
DOI:10.1016/j.bcp.2012.11.016
18. Urrutia PJ, Mena NP, Nunez MT.: The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. *Frontiers in pharmacology* 5:38 (2014)
DOI:/10.3389/fphar.2014.00038
19. Krautwald M, Munch G.: Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease? *Experimental gerontology* 45(10):744-51 (2010)
DOI:10.1016/j.jns.2012.02.018
20. Li J, Liu D, Sun L, Lu Y, Zhang Z.: Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. *Journal of the neurological sciences* 317(1-2):1-5 (2012)
DOI:10.1016/j.jns.2012.02.018
21. Tan, M. S., Yu, J. T., Tan, C. C., Wang, H. F., Meng, X. F., Wang, C., Tan, L.: Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. *Journal of Alzheimer's disease : JAD* 43(2):589-603 (2015)
DOI:10.3233/JAD-140837
22. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S.: Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. *Journal of psychiatric research* 46(6):716-23 (2012)
DOI:10.1016/j.jpsychires.2012.03.003
23. Liu, Y. L., Zhou, Y., Sun, L., Wen, J. T., Teng, S. J., Yang, L., & Du, D. S.: Protective effects of Ginkgo biloba extract 761 on myocardial infarction via improving the

- viability of implanted mesenchymal stem cells in the rat heart. *Molecular medicine reports* 9(4):1112-20 (2014)
DOI:10.3892/mmr.2014.1959
24. Schneider LS.: Ginkgo and AD: key negatives and lessons from GuidAge. *The Lancet. Neurology* 11(10):836-7 (2012)
DOI:10.3892/mmr.2014.1959
 25. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathieux-Fortunet H, Andrieu S: Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *The Lancet. Neurology* 11(10):851-9 (2012)
DOI:10.1016/S1474-4422(12)70206-5
 26. Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O: Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. *International journal of geriatric psychiatry* 26(11):1186-94 (2011)
DOI:10.1002/gps.2662
 27. Ihl R, Tribanek M, Bachinskaya N.: Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761(R)) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial. *Journal of the neurological sciences* 299(1-2):184-7 (2010)
DOI:10.1016/j.jns.2010.08.033
 28. Yen CH, Yang NC, Lee BJ, Lin JY, Hsia S, Lin PT.: The antioxidant status and concentrations of coenzyme Q10 and vitamin E in metabolic syndrome. *TheScientificWorldJournal* 2013:767968 (2013)
DOI:10.1155/2013/767968
 29. Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Jazayeri S, Reza Gohari M.: Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis. *The International journal of neuroscience* 123(11):776-82 (2013)
DOI:10.3109/00207454.2013.801844
 30. Spindler M, Beal MF, Henchcliffe C.: Coenzyme Q10 effects in neurodegenerative disease. *Neuropsychiatric disease and treatment* 5:597-610 (2009)
 31. Shults CW, Haas RH, Passov D, Beal MF.: Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. *Annals of neurology* 42(2):261-4 (1997)
DOI:10.1002/ana.410420221
 32. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S.: Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. *Neurobiology of disease* 18(3):618-27 (2005)
DOI:10.1016/j.nbd.2004.10.021
 33. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB.: Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. *Annals of neurology* 36(6):882-8 (1994)
DOI:10.1002/ana.410360613
 34. Muller T, Buttner T, Gholipour AF, Kuhn W.: Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. *Neuroscience letters* 341(3):201-4 (2003)
 35. McDonald SR, Sohal RS, Forster MJ.: Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. *Free radical biology & medicine* 38(6):729-36 (2005)
DOI:10.1016/j.freeradbiomed.2004.11.014
 36. Mischley LK, Allen J, Bradley R.: Coenzyme Q10 deficiency in patients with Parkinson's disease. *Journal of the neurological sciences* 318(1-2):72-5 (2012)
DOI:10.1016/j.jns.2012.03.023
 37. Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, Gohari MR, Aryaeian N.: Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. *Nutritional neuroscience* 18(4):169-76 (2015)
DOI:10.1179/1476830513Y.0000000106
 38. Speckmann B, Bidmon HJ, Borchardt A, Sies H, Steinbrenner H.: Intestinal selenoprotein P in epithelial cells and in plasma cells. *Archives of biochemistry and*

- biophysics* 541:30-6 (2014)
DOI:10.1016/j.abb.2013.10.011
39. Hellwege JN1, Palmer ND, Ziegler JT, Langefeld CD, Lorenzo C, Norris JM, Takamura T, Bowden DW.: Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics. *Gene* 534(1):33-9 (2014)
DOI:10.1016/j.gene.2013.10.035
 40. Brauer AU, Savaskan NE.: Molecular actions of selenium in the brain: neuroprotective mechanisms of an essential trace element. *Reviews in the neurosciences* 15(1):19-32 (2004)
 41. Steinbrenner H, Sies H.: Selenium homeostasis and antioxidant selenoproteins in brain: implications for disorders in the central nervous system. *Archives of biochemistry and biophysics* 536(2):152-7 (2013)
DOI:10.1016/j.abb.2013.02.021
 42. Xiong S, Markesbery WR, Shao C, Lovell MA.: Seleno-L-methionine protects against beta-amyloid and iron/hydrogen peroxide-mediated neuron death. *Antioxidants & redox signaling* 9(4):457-67 (2007)
DOI:10.1089/ars.2006.1363
 43. Aguilar MV, Jiménez-Jiménez FJ, Molina JA, Meseguer I, Mateos-Vega CJ, González-Muñoz MJ, de Bustos F, Gómez-Escalonilla C, Ort-Pareja M, Zurdo M, Martínez-Para MC.: Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease. *J Neural Transm* 105(10-12):1245-51 (1998)
 44. Wenstrup D, Ehmann WD, Markesbery WR.: Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. *Brain research* 533(1):125-31 (1990)
 45. Cornett CR, Markesbery WR, Ehmann WD.: Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. *Neurotoxicology* 19(3):339-45 (1998)
 46. Ceballos-Picot I, Merad-Boudia M, Nicole A, Thevenin M, Hellier G, Legrain S, Berr C.: Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type--place of the extracellular glutathione peroxidase. *Free radical biology & medicine* 20(4):579-87 (1996)
 47. Clausen J, Jensen GE, Nielsen SA.: Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's disease. *Biological trace element research* 15:179-203 (1998)
 48. Battin EE, Brumaghim JL.: Antioxidant activity of sulfur and selenium: a review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms. *Cell biochemistry and biophysics* 55(1):1-23 (2009)
DOI:10.1007/s12013-009-9054-7
 49. Peters MM, Hill KE, Burk RF, Weeber EJ.: Altered hippocampus synaptic function in selenoprotein P deficient mice. *Molecular neurodegeneration* 1:12 (2006)
DOI:10.4161%2Frna.22290
 50. Iwunze MO, McEwan D.: Peroxynitrite interaction with curcumin solubilized in ethanolic solution. *Cell Mol Biol* 50(6):749-52 (2004)
 51. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ.: Curcumin labels amyloid pathology *in vivo*, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. *Journal of neurochemistry* 102(4):1095-104 (2007)
DOI:10.1111/j.1471-4159.2007.04613.x
 52. Belkacemi A, Doggui S, Dao L, Ramassamy C.: Challenges associated with curcumin therapy in Alzheimer disease. *Expert reviews in molecular medicine* 13:e34 (2011)
DOI:10.1017/S1462399411002055
 53. Harish G, Venkateshappa C, Mythri RB, Dubey SK, Mishra K, Singh N, Vali S, Bharath MM.: Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. *Bioorganic & medicinal chemistry* 18(7):2631-8 (2010)
DOI:10.1016/j.bmc.2010.02.029
 54. Mythri RB, Harish G, Dubey SK, Misra K, Bharath MM.: Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria *in vitro*: implications for Parkinson's disease. *Molecular and cellular biochemistry* 347(1-2):135-43 (2011)
DOI:10.1007/s11010-010-0621-4

55. Pan J, Li H, Ma JF, Tan YY, Xiao Q, Ding JQ, Chen SD.: Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction. *Translational neurodegeneration* 1(1):16 (2012)
DOI:10.1186/2047-9158-1-16
56. Du XX, Xu HM, Jiang H, Song N, Wang J, Xie JX.: Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease. *Neuroscience bulletin* 28(3):253-8 (2012)
DOI:10.1007/s12264-012-1238-2
57. DU P, Tang HY, Li X, Lin HJ, Peng WF, Ma Y, Fan W, Wang X.: Anticonvulsive and antioxidant effects of curcumin on pilocarpine-induced seizures in rats. *Chinese medical journal* 125(11):1975-9 (2012)
58. Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF.: Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. *Molecular neurodegeneration* 7:12 (2012)
DOI:10.1186/1750-1326-7-12
59. Wu J, Zhang Y, Cai Y, Wang J, Weng B, Tang Q, Chen X, Pan Z, Liang G, Yang S.: Discovery and evaluation of piperid-4-one-containing mono-carbonyl analogs of curcumin as anti-inflammatory agents. *Bioorganic & medicinal chemistry* 21(11):3058-65 (2013)
DOI:10.1016/j.bmc.2013.03.057
60. Grubman A, White AR, Liddell JR.: Mitochondrial metals as a potential therapeutic target in neurodegeneration. *British journal of pharmacology* 171(8):2159-73 (2014)
DOI:10.1111/bph.12513
61. Lu J, Duan W, Guo Y, Jiang H, Li Z, Huang J, Hong K, Li C.: Mitochondrial dysfunction in human TDP-43 transfected NSC34 cell lines and the protective effect of dimethoxy curcumin. *Brain research bulletin* 89(5-6):185-90 (2012)
DOI:10.1016/j.brainresbull.2012.09.005
62. Lu JJ, Cai YJ, Ding J.: The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. *Molecular and cellular biochemistry* 360(1-2):253-60 (2012)
DOI:10.1007/s11010-011-1064-2
63. Lu Y, Ding N, Yang C, Huang L, Liu J, Xiang G.: Preparation and *in vitro* evaluation of a folate-linked liposomal curcumin formulation. *Journal of liposome research* 22(2):110-9 (2012)
DOI:10.3109/08982104.2011.627514
64. Bourre JM, Durand G, Pascal G, Youyou A.: Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. *The Journal of nutrition* 119(1):15-22 (1989)
65. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH.: Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. *Lipids* 35(12):1305-12 (2000)
66. Greiner RS, Moriguchi T, Hutton A, Slotnick BM, Salem N.: Rats with low levels of brain docosahexaenoic acid show impaired performance in olfactory-based and spatial learning tasks. *Lipids* 34 Suppl:S239-43 (1999)
67. Wu A, Ying Z, Gomez-Pinilla F.: Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. *Neuroscience* 155(3):751-9 (2008)
DOI:10.1016/j.neuroscience.2008.05.061
68. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA, Cole GM.: Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. *The European journal of neuroscience* 22(3):617-26 (2005)
DOI:10.1111/j.1460-9568.2005.04253.x
69. Miller E, Walczak A, Majsterek I, Kedziora J.: Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. *Journal of neuroimmunology* 257(1-2):97-101 (2013)
DOI:10.1016/j.jneuroim.2013.02.012
70. Karaaslan C, Suzen S.: Antioxidant properties of melatonin and its potential action in diseases. *Current topics in medicinal chemistry* 15(9):894-903 (2015)

71. More SV, Choi DK.: Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. *Molecular neurodegeneration* 10(1):17 (2015)
72. Durmaz R, Ozden H, Kanbak G, Aral E, Arslan OC, Kartkaya K, Uzuner K.: protective effect of dexamabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia. *Neurochemical research* 33(9):1683-91 (2008)
DOI:10.1007/s11064-008-9605-0
73. Zalish M, Lavie V.: Dexamabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury. *Vision research* 43(3):237-42 (2003)
74. Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A.: Dexamabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. *Critical care medicine* 30(3):548-54 (2002)
75. Lemtiri-Chlieh F, Levine ES.: BDNF evokes release of endogenous cannabinoids at layer 2/3 inhibitory synapses in the neocortex. *Journal of neurophysiology* 104(4):1923-32 (2010)
DOI:10.1152/jn.00472.2010
76. Gonzalez-Naranjo P, Campillo NE, Perez C, Paez JA.: Multitarget cannabinoids as novel strategy for Alzheimer disease. *Current Alzheimer research* 10(3):229-39 (2013)
77. Tanveer R, Gowran A, Noonan J, Keating SE, Bowie AG, Campbell VA.: The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats. *The Journal of biological chemistry* 287(41):34709-21 (2012)
DOI:10.1074/jbc.M112.350678
78. Steele M, Stuchbury G, Munch G.: The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. *Experimental gerontology* 42(1-2):28-36 (2007)
DOI:10.1016/j.exger.2006.06.002
79. Shen L, Ji HF.: Vitamin E: supplement versus diet in neurodegenerative diseases. *Trends in molecular medicine* 18(8):443-5 (2012)
DOI:10.1016/j.molmed.2012.04.010
80. Knöchel C, Oertel-Knöchel V, O'Dwyer L, Prvulovic D, Alves G, Kollmann B, Hampel H.: Cognitive and behavioural effects of physical exercise in psychiatric patients. *Progress in neurobiology* 96(1):46-68 (2012)
DOI:10.1016/j.pneurobio.2011.11.007
81. Vidoni ED, Van Sciver A, Johnson DK, He J, Honea R, Haines B, Goodwin J, Laubinger MP, Anderson HS, Kluding PM, Donnelly JE, Billinger SA, Burns JM.: A community-based approach to trials of aerobic exercise in aging and Alzheimer's disease. *Contemporary clinical trials* 33(6):1105-16 (2012)
DOI:10.1016/j.cct.2012.08.002
82. Ferrari CK.: Functional foods and physical activities in health promotion of aging people. *Maturitas* 58(4):327-39 (2007)
DOI:10.1016/j.maturitas.2007.09.011
83. Miller DI, Taler V, Davidson PS, Messier C.: Measuring the impact of exercise on cognitive aging: methodological issues. *Neurobiology of aging* 33(3):622 e29-43 (2012)
DOI:10.1016/j.neurobiolaging.2011.02.020
84. Lee H, Pienaar IS.: Disruption of the blood-brain barrier in Parkinson's disease: curse or route to a cure? *Front Biosci (Landmark Ed)* 19:272-80 (2014)
85. Sanders LH, Greenamyre JT.: Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. *Free radical biology & medicine* 62:111-20 (2013)
DOI:10.1016%2Fj.freeradbiomed.2013.01.003
86. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, Looi WF, Huang SH, Wang H, Chan YH, Halliwell B.: Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. *Free radical biology & medicine* 48(4):560-6 (2010)
DOI:10.1016/j.freeradbiomed.2009.11.026
87. Kong, P., Zhang, B., Lei, P., Kong, X., Zhang, S., Li, D., Zhang, Y.: Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease. *International journal of clinical and experimental medicine* 8(1):431-9 (2015)
88. Sun YX, Wang XH, Xu AH, Zhao JH.: Functional polymorphisms of the MAO gene with Parkinson disease susceptibility: a

- meta-analysis. *Journal of the neurological sciences* 345(1-2):97-105 (2014)
DOI:10.1016/j.jns.2014.07.016
89. Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C3, Zee PC.: Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. *JAMA neurology* 71(4):463-9 (2014)
DOI:10.1001/jamaneurol.2013.6239
 90. Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z, Rogers N, Lewis SJ.: Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. *Sleep medicine* 15(3):342-7 (2014)
DOI:10.1016/j.sleep.2013.10.016
 91. Muller T, Kolf K, Ander L, Woitalla D, Muhlack S.: Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. *Clinical neuropharmacology* 31(3):134-40 (2008)
DOI:10.1097/WNF.0b013e31811510ed
 92. Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.: Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. *Clinical neuropharmacology* 31(1):2-18 (2008)
DOI:10.1097/wnf.0b013e3180645cb0
 93. Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, George-Hyslop PS, Tohyama M.: Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. *The Journal of biological chemistry* 276(46):43446-54 (2001)
DOI:10.1074/jbc.M104096200
 94. Bush AI.: The metallobiology of Alzheimer's disease. *Trends in neurosciences* 26(4):207-14 (2003)
DOI:10.1016/S0166-2236(03)00067-5
 95. Smith DG, Cappai R, Barnham KJ.: The redox chemistry of the Alzheimer's disease amyloid beta peptide. *Biochimica et biophysica acta* 1768(8):1976-90 (2007)
DOI:10.1016/j.bbamem.2007.02.002
 96. Koudinov AR, Berezov TT.: Alzheimer's amyloid-beta (A beta) is an essential synaptic protein, not neurotoxic junk. *Acta neurobiologiae experimentalis* 64(1):71-9 (2004)
 97. Devi L, Ohno M.: PERK mediates eIF2alpha phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease. *Neurobiology of aging* 35(10):2272-81 (2014)
DOI:10.1016/j.neurobiolaging.2014.04.031
 98. White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R.: Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. *Brain research* 842(2):439-44 (1999)
 99. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI.: Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. *The Journal of biological chemistry* 273(21):12817-26 (1998)
 100. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI.: Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. *The Journal of biological chemistry* 275(26):19439-42 (2000)
DOI:10.1074/jbc.C000165200
 101. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI.: Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. *The Journal of biological chemistry* 274(52):37111-6 (1999)
 102. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA.: Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. *Neuroscience letters* 406(3):189-93 (2006)
DOI:10.1016/j.neulet.2006.07.020

103. Kreuter J.: Nanoparticulate systems for brain delivery of drugs. *Advanced drug delivery reviews* 47(1):65-81 (2001) DOI:10.1111/jpi.12099
104. Shea TB, Ortiz D, Nicolosi RJ, Kumar R, Watterson AC.: Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. *Journal of Alzheimer's disease : JAD* 7(4):297-301 (2005)
105. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F.: The future of Alzheimer's disease: the next 10 years. *Progress in neurobiology* 95(4):718-28 (2011) DOI:10.1016/j.pneurobio.2011.11.008
106. He P, Ouyang X, Zhou S, Yin W, Tang C, Laudon M, Tian S.: A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. *Hormones and behavior* 64(1):1-7 (2013) DOI:10.1016/j.yhbeh.2013.04.009
107. Baño Otalora B, Popovic N, Gambini J, Popovic M, Viña J, Bonet-Costa V, Reiter RJ, Camello PJ, Rol MÁ, Madrid JA.: Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APP^{swE}/PS1^{dE9} transgenic model of Alzheimer disease: effects of melatonin or ramelteon. *Chronobiology international* 29(7):822-34 (2012) DOI:10.3109/07420528.2012.699119
108. Yang X, Yang Y, Fu Z, Li Y, Feng J, Luo J, Zhang Q, Wang Q, Tian Q.: Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. *J Psychopharmacol* 25(8):1118-25 (2011) DOI:10.1177/0269881110367723
109. He H, Dong W, Huang F.: Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. *Current neuropharmacology* 8(3):211-7 (2010) DOI:10.2174/157015910792246137
110. Ortiz F, García JA, Acuña-Castroviejo D, Doerrier C, López A, Venegas C, Volt H, Luna-Sánchez M, López LC, Escames G.: The beneficial effects of melatonin against heart mitochondrial impairment during sepsis: inhibition of iNOS and preservation of nNOS. *Journal of pineal research* 56(1):71-81 (2014) DOI:10.1111/jpi.12099
111. Oktem G, Uslu S, Vatansver SH, Aktug H, Yurtseven ME, Uysal A.: Evaluation of the relationship between inducible nitric oxide synthase (iNOS) activity and effects of melatonin in experimental osteoporosis in the rat. *Surgical and radiologic anatomy: SRA* 28(2):157-62 (2006) DOI:10.1007/s00276-005-0065-9
112. Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C.: Alzheimer's disease: new approaches to drug discovery. *Current opinion in chemical biology* 13(3):303-8 (2009) DOI:10.1016/j.cbpa.2009.04.619
113. Quigley HA, Broman AT.: The number of people with glaucoma worldwide in 2010 and 2020. *The British journal of ophthalmology* 90(3):262-7 (2006) DOI:10.1136/bjo.2005.081224
114. Levene RZ.: Low tension glaucoma. Part II. Clinical characteristics and pathogenesis. *Annals of ophthalmology* 12(12):1383 (1980)
115. Levene RZ.: Low tension glaucoma: a critical review and new material. *Survey of ophthalmology* 24(6):621-64 (1980)
116. Weinreb RN.: Evaluating the retinal nerve fiber layer in glaucoma with scanning laser polarimetry. *Arch Ophthalmol* 117(10):1403-6 (1999)
117. Weinreb RN, Levin LA.: Is neuroprotection a viable therapy for glaucoma? *Arch Ophthalmol* 117(11):1540-4 (1999)
118. Crish SD, Calkins DJ.: Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. *Neuroscience* 176:1-11 (2011) DOI:10.1016/j.neuroscience.2010.12.036
119. Payne AJ, Kaja S, Naumchuk Y, Kunjukunju N, Koulen P.: Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. *International journal of molecular sciences* 15(2):1865-86 (2014) DOI:10.3390/ijms15021865
120. Annweiler C, Beauchet O.: Possibility of a new anti-alzheimer's disease pharmaceutical composition combining

- memantine and vitamin D. *Drugs & aging* 29(2):81-91 (2012)
DOI:10.2165/11597550-000000000-00000
121. Cantor LB.: The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. *Expert opinion on pharmacotherapy* 1(4):815-34 (2000)
DOI:10.1517/14656566.1.4.815
122. McKenna DJ, Jones K, Hughes K.: Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. *Alternative therapies in health and medicine* 7(5):70-86, 88-90 (2001)
123. Bent S, Goldberg H, Padula A, Avins AL.: Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. *Journal of general internal medicine* 20(7):657-61 (2005)
DOI:10.1111/j.1525-1497.2005.0121.x
124. Inman DM, Lambert WS, Calkins DJ, Horner PJ.: alpha-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. *PLoS one* 8(6):e65389 (2013)
DOI:10.1371/journal.pone.0065389
125. Prokai-Tatrai K, Xin H, Nguyen V, Szarka S, Blazics B, Prokai L, Koulen P.: 17beta-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an *in vivo* model of glaucoma. *Molecular pharmacology* 10(8):3253-61 (2013)
DOI:10.1021/mp400313u
126. Kaja S, Yang SH, Wei J, Fujitani K, Liu R, Brun-Zinkernagel AM, Simpkins JW, Inokuchi K, Koulen P.: Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Ves1-1L/Homer 1c immunoreactive synaptic connections. *Investigative ophthalmology & visual science* 44(7):3155-62 (2003)
127. Beidoe G, Mousa SA.: Current primary open-angle glaucoma treatments and future directions. *Clin Ophthalmol* 6:1699-707 (2012)
DOI:10.2147/OPHTH.S32933
128. Araie M, Mayama C.: Use of calcium channel blockers for glaucoma. *Progress in retinal and eye research* 30(1):54-71 (2011)
DOI:10.1016/j.preteyeres.2010.09.002
129. Eschweiler GW, Bahr M.: Flunarizine enhances rat retinal ganglion cell survival after axotomy. *Journal of the neurological sciences* 116(1):34-40 (1993)
130. Yamada H, Chen YN, Aihara M, Araie M.: Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. *Brain research* 1071(1):75-80 (2006)
DOI:10.1016/j.brainres.2005.11.072
131. Ogata Y, Kaneko T, Kayama N, Ueno S.: Effects of nilvadipine on retinal microcirculation and systemic circulation. *Nippon Ganka Gakkai zasshi* 104(10):699-705 (2000)
132. Ito, Y., Nakamura, S., Tanaka, H., Tsuruma, K., Shimazawa, M., Araie, M., Hara, H.: Lomerizine, a Ca²⁺ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. *CNS neuroscience & therapeutics* 16(2):103-14 (2010)
DOI:10.1111/j.1755-5949.2.009.0.0081.x
133. Martin KR, Quigley HA, Zack DJ, Levkovitch-Verbin H, Kielczewski J, Valenta D, Baumrind L, Pease ME, Klein RL, Hauswirth WW.: Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. *Investigative ophthalmology & visual science* 44(10):4357-65 (2003)
134. Ren R, Li Y, Liu Z, Liu K, He S.: Long-term rescue of rat retinal ganglion cells and visual function by AAV-mediated BDNF expression after acute elevation of intraocular pressure. *Investigative ophthalmology & visual science* 53(2):1003-11 (2012)
DOI:10.1167/iovs.11-8484
135. Polimeni G, Esposito E, Bevelacqua V, Guarneri C, Cuzzocrea S.: Role of melatonin supplementation in neurodegenerative disorders. *Front Biosci (Landmark Ed)* 19:429-46 (2014)
136. Miljkovic D, Spasojevic I.: Multiple sclerosis: molecular mechanisms and therapeutic opportunities. *Antioxidants & redox signaling* 19(18):2286-334 (2013)
DOI:10.1089/ars.2012.5068

137. Cornelia Schuh, Isabella Wimmer, Simon Hametner, Lukas Haider, Anne-Marie Van Dam, Roland S. Liblau, Ken J. Smith, Lesley Probert, Christoph J. Binder, Jan Bauer, Monika Bradl, Don Mahad, Hans Lassmann: Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. *Acta neuropathologica* 128(2):247-66 (2014)
DOI:10.1007%2Fs00401-014-1263-5
138. Schwarz S, Knorr C, Geiger H, Flachenecker P.: Complementary and alternative medicine for multiple sclerosis. *Mult Scler* 14(8):1113-9 (2008)
DOI:10.1177/1352458508092808
139. Gold R, Linker RA, Stangel M.: Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. *Clin Immunol* 142(1):44-8 (2012)
DOI:10.1016/j.clim.2011.02.017
140. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Brück W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R.: Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain : a journal of neurology* 134(Pt 3):678-92 (2011)
DOI:10.1093/brain/awq386
141. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ.: Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. *The Journal of pharmacology and experimental therapeutics* 341(1):274-84 (2012)
DOI:10.1124/jpet.111.190132
142. Fonseca-Kelly, Z., Nassrallah, M., Uribe, J., Khan, R. S., Dine, K., Dutt, M., & Shindler, K. S.: Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. *Frontiers in neurology* 3:84 (2012)
DOI:10.3389%2Ffneur.2012.00084
143. Mao P, Manczak M, Shirendeb UP, Reddy PH.: MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple

sclerosis. *Biochimica et biophysica acta* 1832(12):2322-31 (2013)
DOI:10.1016/j.bbadis.2013.09.005

Key Words: Neurodegeneration, Redox Therapy, Oxidative Stress, Review

Send correspondence to: Elzbieta Miller, Department of Physical Medicine, Medical University of Lodz, Hallera Square, 1, Lodz, Poland, Tel: 48 42 272 50 55, Fax: 48 42 272 50 52, E-mail: elzbieta.dorota.miller@umed.lodz.pl